Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1998-6-24
|
| pubmed:abstractText |
Antithrombin III (ATIII) concentrates are employed as therapy for congenital or acquired deficiencies. These concentrates are obtained from Cohn's fraction IV1. To improve yields, purity and safety, our group developed a procedure to obtain a pasteurized ATIII concentrate from the supernatant of Cohn's fraction II + III including a highly efficient heparin affinity chromatography purification and pasteurization as a viral inactivation step.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0390-6078
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
83
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
305-11
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9592979-Antithrombin III,
pubmed-meshheading:9592979-Chromatography, Affinity,
pubmed-meshheading:9592979-Evaluation Studies as Topic,
pubmed-meshheading:9592979-Humans,
pubmed-meshheading:9592979-Safety,
pubmed-meshheading:9592979-Sterilization,
pubmed-meshheading:9592979-Virus Diseases
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained through affinity chromatography.
|
| pubmed:affiliation |
Research and Development Area, Instituto Grifols, Barcelona, Spain.
|
| pubmed:publicationType |
Journal Article
|